Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2025
0mins
Source: Business Insider
Financial Overview: As of December 31, 2024, Turnstone Biologics Corp. reported cash, cash equivalents, and short-term investments totaling $28.9 million.
Company Developments: Turnstone Biologics has been downgraded to Neutral from Overweight due to challenges with TIL therapy and has decided to halt all clinical studies while exploring strategic alternatives.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
